Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaTreatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infectionsColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyRenal and neurological side effects of colistin in critically ill patientsAntimicrobial Peptide Resistance of Vibrio cholerae Results from an LPS Modification Pathway Related to Nonribosomal Peptide SynthetasesWhat's new in multidrug-resistant pathogens in the ICU?Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsColistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.Therapy of Infections due to Carbapenem-Resistant Gram-Negative PathogensTreatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Validation of a model to predict the risk of nephrotoxicity in patients receiving colistinTrough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.Pseudomonas aeruginosa: resistance to the maxDetermination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protoThe use of intravenous colistin among children in the United States: results from a multicenter, case seriesWorldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene.Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized PatientsIncidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patientsCombination therapy for treatment of infections with gram-negative bacteria.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rodsClinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infectionImpact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosaPharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsOptimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaInfluence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative BacilliTreatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patientsFosfomycinMultidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.A 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek HospitalTargeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock.In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.Multidrug-resistant Gram-negative infections: the use of colistin.Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.
P2860
Q24612271-F08E9532-7299-42F6-B61F-0E70B6253D7DQ26991886-CA15435A-FAE0-4EF5-AACC-0D97950E9019Q27014993-3C4555CF-1987-4C8F-BF2D-A3ECABD7448EQ27499294-72FA1A03-BE2E-40B5-9B41-056E5991312BQ27684837-243462FA-2E55-4946-8B4A-DF63AC8F4E0AQ28071346-73B82C16-BE17-4525-93D0-9C7320A5603BQ28082546-DC59571F-F259-4ED8-9218-4A1229641FC3Q34015375-14834520-E5A4-44AE-BFF4-4359F60FC8F4Q34303970-606467E8-58F3-401E-BC4D-77DD39758171Q34327857-42E129BB-C7A8-441D-BAD5-03DE88E55B67Q34596336-82B60313-16BF-4D27-B5D0-6B04161FA35BQ34955582-91AEFCDE-9D36-4383-B97F-67B4E8796087Q34974577-7C2F0B93-F112-436B-B806-40617CF59874Q35084559-E043C7EE-017B-47F6-A279-18F2D7BC2A74Q35214110-C8378A22-9C40-4DDC-A116-C7E41FA91B0EQ35218683-D71EE0E3-4C77-44E2-B8F5-61B79AEA6029Q35592264-26AABE5C-F9E2-4322-97DE-BC30543AF17EQ35806497-642775CD-4BB2-4D9D-B592-17C2821A48D4Q35848981-5450081E-0DD8-4ADC-A93F-5A1C1AB7F7F7Q35941403-BA76E592-E0B8-4999-B4F0-3D6109C4E8B9Q36156077-0EC84881-817E-4C9A-BBFE-EBAC75CF9BCCQ36158501-FD61ECC4-B536-4EC3-9A7C-930B4D56FB6BQ36178130-FAC53B70-A83F-4E5C-B408-B836F0676165Q36240813-CC035AC9-140B-4E03-B5C7-FC0E5ACD43A5Q36335694-4E4C1C9F-87B7-4962-AD87-BA4F9E19DB4CQ36361921-93697321-6BC4-4762-8B25-8447EFAC9A42Q36363261-AD523B2D-52CB-48B4-9CF0-10B9035DF690Q36438905-3CF72231-F8E1-48F5-B5F5-5D2D9F412F91Q36556499-ED37302A-AFC1-496F-B37E-E8D98674C257Q36667079-9C030785-7529-447F-9112-E99BEA6F7212Q36675246-2FDCB681-BE89-416B-AD2D-AD8EBE059E5AQ36761826-075FB529-5BD3-44C4-8DAD-078DD2FE42CAQ37306655-97D79E50-FAC0-469B-85CA-A6B3637547CFQ37377897-27900AC0-2C93-4B71-9806-BDE81ED78204Q37562099-107E7523-D086-4E1D-BEF0-E4A73AF1A4CAQ37563005-97E9016A-7D84-4633-B3F0-967516B05A37Q37712983-910762D9-5020-4757-BB34-28709E5B615EQ37785545-A8441C48-4F00-4918-9829-12457493A4ECQ37838126-458F08B4-EAD2-4A5A-8ABB-96ECF54BDC29Q37869910-08BF7C9F-71CD-476C-B982-42920DBA1FC4
P2860
Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Colistin therapy for microbiol ...... cohort study of 258 patients.
@en
Colistin therapy for microbiol ...... cohort study of 258 patients.
@nl
type
label
Colistin therapy for microbiol ...... cohort study of 258 patients.
@en
Colistin therapy for microbiol ...... cohort study of 258 patients.
@nl
prefLabel
Colistin therapy for microbiol ...... cohort study of 258 patients.
@en
Colistin therapy for microbiol ...... cohort study of 258 patients.
@nl
P2093
P50
P1476
Colistin therapy for microbiol ...... cohort study of 258 patients.
@en
P2093
Anastasios Kapaskelis
Dimitra Nikita
Drosos E Karageorgopoulos
Elda Ioannidou
Vangelis G Alexiou
P304
P356
10.1016/J.IJANTIMICAG.2009.10.005
P577
2009-12-16T00:00:00Z